Baxter International Inc. ($BAX) Stock Forecast: Down 6.4% Today

What is Baxter International Inc.?

Baxter International Inc. (NYSE: BAX) operates in the healthcare sector, specializing in treatments for various medical conditions like hemophilia, kidney disease, and immune disorders. The company recently saw a notable downward trend in its stock performance.

Why is Baxter International Inc. going down?

BAX stock is down 6.4% on Aug 13, 2024 18:02

• The company faced a sharp decline in its stock value after announcing the sale of its Kidney Care unit, Vantive, to The Carlyle Group for $3.8 billion.
• Market sentiment turned negative following this announcement, with concerns arising about the potential impact of divesting such a significant segment.
• Investors seem unsure about Baxter International Inc.'s future growth trajectory without its kidney care division, prompting a selloff of shares.
• While the sale could signify a strategic realignment for Baxter, the initial market reaction appears cautious and doubtful.

BAX Price Chart

BAX News

Shock deal! Carlyle to snap up Baxter’s kidney care business for $3.8bn—Here’s why it matters

In a landmark move for the medtech industry, Carlyle Group (NASDAQ) has announced its decision to acquire Baxter International Inc.’s (NYSE) Kidney Care segment for a substantial $3.8 billion. This transaction will see the segment rebranded as Vantive and marks a significant shift in the global kidney care market. The acquisition, slated to close in […]

https://business-news-today.com/shock-deal-carlyle-to-snap-up-baxters-kidney-care-business-for-3-8bn-heres-why-it-matters/

Baxter Seals $3.8B Deal With Carlyle For Its Kidney Care Segment - Baxter Intl ( NYSE:BAX )

On Tuesday, Baxter International Inc BAX agreed to sell its Kidney Care segment, Vantive, for $3.8 billion to The Carlyle Group Inc CG Baxter will receive approximately $3.5 billion in cash, with net after-tax proceeds currently estimated at approximately $3 billion.

https://www.benzinga.com/news/large-cap/24/08/40342215/baxter-seals-3-8b-deal-with-carlyle-for-its-kidney-care-segment

Baxter Stock Falls After it Unloads Kidney Care Division in $3.8B Deal

Baxter International is selling its kidney treatment division to Carlyle Group for $3.8 billion, the companies said Tuesday.

https://www.investopedia.com/baxter-unloads-kidney-care-division-in-usd3-8b-deal-8694443

Tuesday''s rapid fire: Home Depot, On Holding, Baxter, Hormel Foods and Micron

CNBC''s Jim Cramer on Tuesday offered his thinking on five stocks outside the Investing Club portfolio.

https://www.cnbc.com/video/2024/08/13/tuesdays-rapid-fire-home-depot-on-holding-baxter-hormel-foods-and-micron.html

4 stocks to watch on Tuesday: HD, BAX and more

No summary available.

https://seekingalpha.com/news/4139168-4-stocks-to-watch-on-tuesday-hd-bax-and-more?source=feed_sector_healthcare

Trending Today

Nike Inc. ($NKE) Stock Forecast: Up 6.2% Today

GameStop Corp. ($GME) Stock Forecast: Up 7.9% Today

Enphase Energy Inc. ($ENPH) Stock Forecast: Down 5.9% Today

NRG Energy Inc. ($NRG) Stock Forecast: Up 5.1% Today

Novo Nordisk A/S ($NVO) Stock Forecast: Down 5.3% Today

Bittensor ($TAO) Crypto Forecast: Up 10.7% Today

Ethereum ($ETH) Crypto Forecast: Up 5.2% Today

Aurora Cannabis Inc. ($ACB) Stock Forecast: Down 5.2% Today

Hims & Hers Health Inc. ($HIMS) Stock Forecast: Down 5.3% Today

FedEx Corporation ($FDX) Stock Forecast: Down 15.5% Today

Baxter International Inc. Price History

09.01.2024 - BAX Stock was up 5.0%

• Baxter International Inc. beat Q4 expectations, with revenue exceeding guidance and sales growth driven by strong performance in various segments.
• The company's strategic initiatives with a new operating model without the BioPharma Solutions unit contributed to its positive performance.
• BAX's fourth-quarter and full-year results reflect solid demand for its medically essential products, indicating strong market demand.
• The positive earnings and sales results likely contributed to the bullish movement in BAX's stock today.

08.00.2024 - BAX Stock was up 5.7%

• 1. The pharmaceutical contract manufacturing market is expected to experience significant growth in the coming years, with North America leading the way. This positive outlook for the industry could have contributed to the bullish movement in BAX stock.
• 2. BAX's expertise in contract manufacturing positions them well to benefit from the expected market growth. Investors may have recognized this potential and increased their positions in the stock, driving the bullish movement.
• 3. The bullish movement in BAX stock could also be a result of increased investor confidence in the overall pharmaceutical sector, as indicated by the positive market growth forecast. This positive sentiment may have spilled over to BAX, leading to the upward movement in the stock price.

08.01.2024 - BAX Stock was up 1.4%

• The strong bullish movement of BAX today can be attributed to the following factors:
• 1. Baxter International reported better-than-expected earnings and revenue for the fourth quarter, indicating strong financial performance.
• 2. Despite missing the Street estimates, the company's Q4 profit increased from the previous year, which could have instilled confidence in investors.
• 3. The anticipation of positive key metrics and potential growth in elective surgical procedures may have contributed to the bullish market movement.
• 4. The boost in sales from Hillrom's products, along with favorable currency movement, could have further bolstered investor sentiment.
• Overall, the combination of Baxter International's solid financial performance, positive key metrics, and potential growth drivers likely fueled the bullish movement of BAX today.

05.02.2024 - BAX Stock was up 5.1%

• Baxter International is exploring strategic options for its Kidney Care business, potentially signaling a positive restructuring that investors could view favorably.
• The company's participation in various conferences, including the Raymond James 45th Annual Institutional Investors Conference, may have generated investor interest and confidence in Baxter's future.
• The announcement of Baxter's CFO presenting at these conferences likely reassured investors about the company's financial strength and growth opportunities.
• These strategic initiatives and public appearances by Baxter International's executives potentially influenced the stock's bullish movement today.

05.06.2024 - BAX Stock was up 4.6%

• The strong bullish movement of Baxter International today could be linked to the market's positive reception of the company's robust growth across all geographies.
• Despite pandemic-related disruptions affecting sales, investors appear confident in Baxter International's transformational initiatives, which are apparently viewed as promising for future growth.
• The bullish trend indicates that investors are placing more emphasis on the company's growth potential and less on the short-term challenges posed by the ongoing pandemic.

17.06.2024 - BAX Stock was up 5.5%

• The bullish movement in Baxter's stock today can be attributed to the company's recall of the Volara system single-patient use circuit. Despite the recall, investors seem to be reacting positively to the company's proactive approach to ensuring patient safety and addressing the issue promptly.
• The rise in Baxter's shares could also be influenced by the recent stability shown by the stock after a previous decline in the first half of 2024. Investors may be gaining confidence in the company's ability to navigate challenges and maintain a strong market position.
• Overall, Baxter's stock performance reflects a mix of short-term positive momentum from addressing the recall issue and long-term investor sentiment regarding the company's resilience and potential for growth in the healthcare sector.

13.07.2024 - BAX Stock was down 6.7%

• The recent divestment of Baxter International's renal care and acute therapies business may have sparked concerns among investors, impacting the stock's performance negatively.
• Despite surpassing Q2 expectations and adjusting its outlook, the decision to divest its kidney care unit could have prompted a tepid market reaction, creating uncertainty about the company's financial future.
• External factors like Home Depot's disappointing outlook and escalating tensions in the Middle East might have compounded the bearish market sentiment, affecting Baxter International's stock price as well.
• Investor apprehension regarding Baxter's growth prospects post-divestiture led to a sell-off in the stock, with lingering doubts about its ability to sustain growth.

13.07.2024 - BAX Stock was down 6.4%

• The company faced a sharp decline in its stock value after announcing the sale of its Kidney Care unit, Vantive, to The Carlyle Group for $3.8 billion.
• Market sentiment turned negative following this announcement, with concerns arising about the potential impact of divesting such a significant segment.
• Investors seem unsure about Baxter International Inc.'s future growth trajectory without its kidney care division, prompting a selloff of shares.
• While the sale could signify a strategic realignment for Baxter, the initial market reaction appears cautious and doubtful.

13.07.2024 - BAX Stock was down 7.2%

• Baxter International's decision to sell off its renal care and acute therapies division indicates a shift in its focus, potentially sparking concerns among investors regarding future growth.
• The acquisition of Baxter's kidney-care spinoff Vantive by Carlyle Group for $3.8 billion could be causing uncertainty among investors about its impact on Baxter's finances and overall business strategy.
• Factors such as negative guidance from Home Depot and escalating tensions in the Middle East are influencing the broader market sentiment, potentially contributing to the downturn in Baxter's stock.
• In light of these strategic changes and external market conditions, investors might be reassessing their positions in Baxter International, resulting in downward pressure on the stock.

06.07.2024 - BAX Stock was up 5.4%

• Baxter International Inc. experienced a strong bullish movement today following its second-quarter earnings report.
• The company beat earnings and revenue estimates for Q2, with sales exceeding expectations and growing across all segments.
• Baxter raised its earnings, adjusted earnings, and sales growth guidance for the full-year 2024, indicating strong confidence in its future performance.
• The positive market movement can be attributed to the company's strong financial results and optimistic outlook, showcasing its ability to deliver value to shareholders and drive growth in the healthcare sector.

06.07.2024 - BAX Stock was up 6.9%

• Baxter International Inc. (BAX) experienced a strong bullish movement today.
• The bullish market movement can be attributed to Baxter's better-than-expected second-quarter earnings and sales, reflecting solid demand for its medically essential products.
• The company beat analyst estimates for both earnings per share (EPS) and revenue for Q2 2024, leading to a positive outlook and an increase in its full-year EPS guidance.
• The strong performance across all segments, particularly in pharmaceuticals, contributed to exceeding sales growth expectations, driving investor confidence and pushing the stock price higher.

06.07.2024 - BAX Stock was up 7.2%

• Baxter International Inc. (BAX) announced robust financial results for the second quarter, prompting an increase in its earnings, adjusted earnings, and sales growth guidance for the entire fiscal year of 2024.
• The company's Q2 earnings performance exhibited improvement compared to the corresponding period last year, signaling positive growth and overall performance.
• Despite the contrarian investment approach discussed elsewhere, which emphasizes seeking undervalued assets, Baxter's solid fundamentals and positive guidance have evidently rewarded investors with considerable returns.
• The optimistic sentiment surrounding MedTech stocks, including Baxter International Inc. (BAX), in anticipation of their earnings announcements, also contributed to the stock's bullish trajectory today.